세계의 색소침착증 치료 시장 : 치료 유형별, 질환 유형별 예측(2024-2032년)

Pigmentation disorder treatment market size is likely to register 5.8% CAGR between 2024 to 2032, driven by the increasing awareness among the global population about pigmentation disorders and their impact on skin health. As individuals are becoming more conscious about their appearance and seeking to address skin concerns, the demand for advanced pigmentation treatments is on the rise. Additionally, advancements in dermatological research and medical technology have led to the development of innovative treatment options.

With increasing longevity and exposure to environmental factors like UV radiation, the prevalence of pigmentation disorders, such as melasma, hyperpigmentation, and vitiligo is further growing. As per Global Vitiligo Foundation, vitiligo affects 70 million people worldwide, with no barriers based on race, ethnicity, or gender. Around 20-35% of vitiligo patients are children. As a result, there is a growing demand for safe, effective, and minimally invasive treatment options to manage these conditions. The growing influence of social media and beauty standards has fueled the desire for flawless skin, further driving the demand for pigmentation treatments

The overall industry is segmented the into treatment type, type of disorder, and region.

Based on treatment type, the pigmentation disorder treatment market value from the procedures segment is anticipated to witness 5.5% CAGR through 2032. This is due to the increasing demand for advanced dermatological procedures aimed at addressing pigmentation disorders effectively. Procedures, such as laser therapy, chemical peels, microdermabrasion, and intense pulsed light (IPL) treatments offer targeted and precise solutions for various pigmentation concerns. Moreover, advancements in procedural techniques and technologies are improving treatment outcomes while minimizing downtime and side effects for enhancing patient satisfaction.

In terms of type of disorder, the hyperpigmentation segment in the pigmentation disorder treatment market is estimated to record 5.7% CAGR from 2024 to 2032, due to its widespread prevalence and increasing awareness among consumers. With factors, such as sun exposure, hormonal fluctuations, and aging contributing to the development of hyperpigmentation, there is a growing demand for effective treatment options to address this common skin concern. Advancements in treatment modalities tailored specifically for hyperpigmentation, along with the growing availability of professional skincare services are also favoring the segment growth.

Asia Pacific pigmentation disorder treatment industry size will witness rapid expansion at 6.4% CAGR between 2024-2032, attributed to the diverse population and varying climate conditions. This increased incidence, coupled with rising disposable incomes and growing awareness about skincare is fueling the demand for effective treatment options. The expanding availability of advanced dermatological procedures and skincare technologies along with the rising adoption of cosmeceuticals will further propel the market growth in the Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing adoption of advanced skin care procedures
    • 3.2.1.2 Increasing prevalence of pigmentation disorders
    • 3.2.1.3 Growing expenditure on dermatological treatments
    • 3.2.1.4 Rising awareness regarding skin health among younger population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of cosmetic procedures
    • 3.2.2.2 Lack of reimbursement policies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 By type
    • 5.2.1.1 Corticosteroids
    • 5.2.1.2 Melanocyte-stimulating hormone
    • 5.2.1.3 Other drugs
  • 5.2.2 By route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Topical
    • 5.2.2.3 Other routes of administrations
  • 5.2.3 By distribution channel
    • 5.2.3.1 Hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Procedures
  • 5.3.1 By type
    • 5.3.1.1 Laser treatment
    • 5.3.1.2 Phototherapy
    • 5.3.1.3 Dermabrasion
    • 5.3.1.4 Other procedures
  • 5.3.2 By end-user
    • 5.3.2.1 Hospitals
    • 5.3.2.2 Dermatology clinics
    • 5.3.2.3 Aesthetic centers
    • 5.3.2.4 Other end-users

Chapter 6 Market Estimates and Forecast, By Type of Disorder, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypopigmentation
  • 6.2.1 Vitiligo
  • 6.2.2 Albinism
  • 6.2.3 Other hypopigmentations
• 6.3 Hyperpigmentation
  • 6.3.1 Melasma
  • 6.3.2 Lentigines
  • 6.3.3 Post-inflammatory hyperpigmentation (PIH)
  • 6.3.4 Other hyperpigmentations

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 7.1 Key trends, by region
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 AbbVie Inc.
• 8.2 Candela Corporation
• 8.3 Cipher Pharmaceuticals Inc.
• 8.4 Galderma
• 8.5 GSK plc
• 8.6 Incyte
• 8.7 L'Oréal Paris
• 8.8 Novartis AG
• 8.9 Pfizer Inc.
• 8.10 Pierre Fabre group
• 8.11 Shiseido Company Limited